15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer.

Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med (2009) 10.01

Eicosanoids and cancer. Nat Rev Cancer (2010) 5.96

Regulation of immune responses by prostaglandin E2. J Immunol (2012) 3.93

Prostaglandins and cancer. Gut (2005) 3.44

Cox-2 is regulated by Toll-like receptor-4 (TLR4) signaling: Role in proliferation and apoptosis in the intestine. Gastroenterology (2006) 2.78

The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene (2009) 2.72

15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci U S A (2006) 2.41

Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer. Breast Cancer Res (2007) 2.03

NAD+-dependent 15-hydroxyprostaglandin dehydrogenase regulates levels of bioactive lipids in non-small cell lung cancer. Cancer Prev Res (Phila) (2008) 1.71

15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors. Proc Natl Acad Sci U S A (2009) 1.65

Stable-isotope dilution LC–MS for quantitative biomarker analysis. Bioanalysis (2010) 1.56

Synthetic triterpenoid induces 15-PGDH expression and suppresses inflammation-driven colon carcinogenesis. J Clin Invest (2014) 1.46

Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward. Clin Cancer Res (2010) 1.44

Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer. Gastroenterology (2015) 1.35

Pro-inflammatory prostaglandins and progression of colorectal cancer. Cancer Lett (2008) 1.32

Regulation of inflammation in cancer by eicosanoids. Prostaglandins Other Lipid Mediat (2011) 1.31

Omega-3 polyunsaturated fatty acids inhibit hepatocellular carcinoma cell growth through blocking beta-catenin and cyclooxygenase-2. Mol Cancer Ther (2009) 1.31

Multifaceted roles of PGE2 in inflammation and cancer. Semin Immunopathol (2012) 1.29

The tumor microenvironment in colorectal carcinogenesis. Cancer Microenviron (2010) 1.23

Epithelia: lymphocyte interactions in the gut. Immunol Rev (2007) 1.15

Inhibition of 11beta-hydroxysteroid dehydrogenase type II selectively blocks the tumor COX-2 pathway and suppresses colon carcinogenesis in mice and humans. J Clin Invest (2009) 1.14

15-oxo-Eicosatetraenoic acid, a metabolite of macrophage 15-hydroxyprostaglandin dehydrogenase that inhibits endothelial cell proliferation. Mol Pharmacol (2009) 1.10

Prostaglandins in cancer cell adhesion, migration, and invasion. Int J Cell Biol (2012) 1.09

Urinary prostaglandin E2 metabolite and risk for colorectal adenoma. Cancer Prev Res (Phila) (2011) 1.08

Aspirin and the risk of colorectal cancer in relation to the expression of 15-hydroxyprostaglandin dehydrogenase (HPGD). Sci Transl Med (2014) 1.07

Microsomal prostaglandin E synthase-2 is not essential for in vivo prostaglandin E2 biosynthesis. Prostaglandins Other Lipid Mediat (2008) 1.05

Hypoxia activates the cyclooxygenase-2-prostaglandin E synthase axis. Carcinogenesis (2009) 1.05

Repression of 15-hydroxyprostaglandin dehydrogenase involves histone deacetylase 2 and snail in colorectal cancer. Cancer Res (2008) 1.04

An inflammatory mediator, prostaglandin E2, in colorectal cancer. Cancer J (2013) 1.01

15-hydroxyprostaglandin dehydrogenase (15-PGDH) and lung cancer. Prostaglandins Other Lipid Mediat (2007) 0.98

Bioactive food components, inflammatory targets, and cancer prevention. Cancer Prev Res (Phila) (2009) 0.96

Mechanistic aspects of COX-2 expression in colorectal neoplasia. Recent Results Cancer Res (2013) 0.95

Impacts of cytosolic phospholipase A2, 15-prostaglandin dehydrogenase, and cyclooxygenase-2 expressions on tumor progression in colorectal cancer. Yonsei Med J (2010) 0.94

Genetic variation in prostaglandin E2 synthesis and signaling, prostaglandin dehydrogenase, and the risk of colorectal adenoma. Cancer Epidemiol Biomarkers Prev (2010) 0.94

The connection between lymphangiogenic signalling and prostaglandin biology: a missing link in the metastatic pathway. Oncotarget (2012) 0.94

miR-21 targets 15-PGDH and promotes cholangiocarcinoma growth. Mol Cancer Res (2014) 0.93

Loss of 15-hydroxyprostaglandin dehydrogenase increases prostaglandin E2 in pancreatic tumors. Pancreas (2010) 0.93

15-PGDH is reduced and induces apoptosis and cell cycle arrest in gastric carcinoma. World J Gastroenterol (2012) 0.93

The Crosstalk of PTGS2 and EGF Signaling Pathways in Colorectal Cancer. Cancers (Basel) (2011) 0.92

Genetic variation in 15-hydroxyprostaglandin dehydrogenase and colon cancer susceptibility. PLoS One (2013) 0.91

Bile acids inhibit NAD+-dependent 15-hydroxyprostaglandin dehydrogenase transcription in colonocytes. Am J Physiol Gastrointest Liver Physiol (2009) 0.91

11-Oxoeicosatetraenoic acid is a cyclooxygenase-2/15-hydroxyprostaglandin dehydrogenase-derived antiproliferative eicosanoid. Chem Res Toxicol (2011) 0.91

Crucial role of macrophage selenoproteins in experimental colitis. J Immunol (2014) 0.91

Rebamipide, a mucoprotective drug, inhibits NSAIDs-induced gastric mucosal injury: possible involvement of the downregulation of 15-hydroxyprostaglandin dehydrogenase. J Clin Biochem Nutr (2011) 0.90

Targeting the eicosanoid pathway in non-small-cell lung cancer. Expert Opin Ther Targets (2009) 0.88

Restoration of leukotriene B(4)-12-hydroxydehydrogenase/15- oxo-prostaglandin 13-reductase (LTBDH/PGR) expression inhibits lung cancer growth in vitro and in vivo. Lung Cancer (2009) 0.87

Analysis of endogenous glutathione-adducts and their metabolites. Biomed Chromatogr (2010) 0.87

Targeted chiral lipidomics analysis of bioactive eicosanoid lipids in cellular systems. BMB Rep (2009) 0.87

Oncolytic herpes simplex virus 1 encoding 15-prostaglandin dehydrogenase mitigates immune suppression and reduces ectopic primary and metastatic breast cancer in mice. J Virol (2011) 0.87

Combined histone deacetylase and cyclooxygenase inhibition achieves enhanced antiangiogenic effects in lung cancer cells. Mol Carcinog (2011) 0.86

A study of prostaglandin pathway genes and interactions with current nonsteroidal anti-inflammatory drug use in colorectal adenoma. Cancer Prev Res (Phila) (2012) 0.86

miR-485-5p binding site SNP rs8752 in HPGD gene is associated with breast cancer risk. PLoS One (2014) 0.86

Limited effect of anti-rheumatic treatment on 15-prostaglandin dehydrogenase in rheumatoid arthritis synovial tissue. Arthritis Res Ther (2012) 0.85

Decreased expression of 15-hydroxyprostaglandin dehydrogenase in gastric carcinomas. Yonsei Med J (2008) 0.85

Butyrate suppresses mRNA increase of osteopontin and cyclooxygenase-2 in human colon tumor tissue. Carcinogenesis (2011) 0.85

CXCR4 in Cancer and Its Regulation by PPARgamma. PPAR Res (2008) 0.85

Pathogenesis of colorectal carcinoma and therapeutic implications: the roles of the ubiquitin-proteasome system and Cox-2. J Cell Mol Med (2007) 0.84

MicroRNA and AU-rich element regulation of prostaglandin synthesis. Cancer Metastasis Rev (2011) 0.84

Retracted 15-hydroxyprostaglandin dehydrogenase-derived 15-keto-prostaglandin E2 inhibits cholangiocarcinoma cell growth through interaction with peroxisome proliferator-activated receptor-γ, SMAD2/3, and TAP63 proteins. J Biol Chem (2013) 0.84

Increase in intracellular PGE2 induces apoptosis in Bax-expressing colon cancer cell. BMC Cancer (2011) 0.83

Colonic 15-PGDH levels are stable across distance and time and are not perturbed by aspirin intervention. Dig Dis Sci (2013) 0.83

15-PGDH inhibits hepatocellular carcinoma growth through 15-keto-PGE2/PPARγ-mediated activation of p21WAF1/Cip1. Oncogene (2013) 0.82

Expression of 15-hydroxyprostaglandin dehydrogenase and cyclooxygenase-2 in non-small cell lung cancer: Correlations with angiogenesis and prognosis. Oncol Lett (2014) 0.82

Targeting inflammation: multiple innovative ways to reduce prostaglandin E₂. Pharm Pat Anal (2013) 0.82

Genetic variability in key genes in prostaglandin E2 pathway (COX-2, HPGD, ABCC4 and SLCO2A1) and their involvement in colorectal cancer development. PLoS One (2014) 0.81

Targeted Cox2 gene deletion in intestinal epithelial cells decreases tumorigenesis in female, but not male, ApcMin/+ mice. Mol Oncol (2013) 0.80

Inactivating mutation in the prostaglandin transporter gene, SLCO2A1, associated with familial digital clubbing, colon neoplasia, and NSAID resistance. Cancer Prev Res (Phila) (2014) 0.80

Celecoxib enhances the efficacy of 15-hydroxyprostaglandin dehydrogenase gene therapy in treating murine breast cancer. J Cancer Res Clin Oncol (2013) 0.80

Prostaglandin E2-induced colonic secretion in patients with and without colorectal neoplasia. BMC Gastroenterol (2010) 0.80

Colorectal neoplasia goes with the flow: prostaglandin transport and termination. Cancer Prev Res (Phila) (2008) 0.79

Cellular uptake and antiproliferative effects of 11-oxo-eicosatetraenoic acid. J Lipid Res (2013) 0.78

Effect of ginger root on cyclooxygenase-1 and 15-hydroxyprostaglandin dehydrogenase expression in colonic mucosa of humans at normal and increased risk for colorectal cancer. Eur J Cancer Prev (2013) 0.78

Regulation of the prostaglandin pathway during development of invasive bladder cancer in mice. Prostaglandins Other Lipid Mediat (2008) 0.78

Resveratrol Treatment Inhibits Proliferation of and Induces Apoptosis in Human Colon Cancer Cells. Med Sci Monit (2016) 0.78

Relationship between 15-hydroxyprostaglandin dehydrogenase and gastric adenocarcinoma. Ann Surg Treat Res (2014) 0.77

Targeted chiral analysis of bioactive arachidonic Acid metabolites using liquid-chromatography-mass spectrometry. Metabolites (2012) 0.76

Prognostic implication of 15-hydroxyprostaglandin dehydrogenase down-regulation in patients with colorectal cancer. J Korean Soc Coloproctol (2012) 0.75

11β-Hydroxysteroid Dehydrogenase Type II is a Potential Target for Prevention of Colorectal Tumorigenesis. J Oncobiomarkers (2013) 0.75

Role of Urinary Biomarkers in the Diagnosis of Adenoma and Colorectal Cancer: A Systematic Review and Meta-Analysis. J Cancer (2016) 0.75

Cyclooxygenase and prostaglandin in cancer. J Korean Soc Coloproctol (2012) 0.75

ASPirin Intervention for the REDuction of colorectal cancer risk (ASPIRED): a study protocol for a randomized controlled trial. Trials (2017) 0.75

Cyclooxygenase-2 knockdown using retinoic acid chalcone (RAC), a promising therapeutic strategy for colon cancer. Am J Cancer Res (2015) 0.75

15-Hydroxyprostaglandin dehydrogenase as a marker in colon carcinogenesis: analysis of the prostaglandin pathway in human colonic tissue. Intest Res (2017) 0.75

Role of 15-hydroxyprostaglandin dehydrogenase down-regulation on the prognosis of hepatocellular carcinoma. Clin Mol Hepatol (2014) 0.75

Nicotinamide Mononucleotide Adenylyl Transferase 2: A Promising Diagnostic and Therapeutic Target for Colorectal Cancer. Biomed Res Int (2016) 0.75

Novel contraceptive targets to inhibit ovulation: the prostaglandin E2 pathway. Hum Reprod Update (2015) 0.75

MicroRNA-21 regulates prostaglandin E2 signaling pathway by targeting 15-hydroxyprostaglandin dehydrogenase in tongue squamous cell carcinoma. BMC Cancer (2016) 0.75

Colonic Saturated Fatty Acid Concentrations and Expression of COX-1, but not Diet, Predict Prostaglandin E2 in Normal Human Colon Tissue. Nutr Cancer (2016) 0.75

Identifying and Creating the Next Generation of Community-Based Cancer Prevention Studies: Summary of a National Cancer Institute Think Tank. Cancer Prev Res (Phila) (2016) 0.75

Three-dimensional culture system identifies a new mode of cetuximab resistance and disease-relevant genes in colorectal cancer. Proc Natl Acad Sci U S A (2017) 0.75

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med (2004) 30.26

Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol (1995) 9.03

Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion. Cancer Cell (2003) 3.87

Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res (1998) 3.79

Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem (2001) 3.69

Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med (2002) 3.47

Altered eicosanoid levels in human colon cancer. J Lab Clin Med (1993) 3.32

Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci (2003) 2.91

Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem (2003) 2.65

Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta. Cancer Cell (2004) 2.60

Prostaglandin catabolizing enzymes. Prostaglandins Other Lipid Mediat (2002) 2.36

Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer. Anal Biochem (2004) 2.24

The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer (1993) 2.23

Patients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E2. Gut (1994) 1.72

Metabolism of PGE2 by prostaglandin dehydrogenase is essential for remodeling the ductus arteriosus. Nat Med (2002) 1.61

Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis. Int J Cancer (2001) 1.61

Prostaglandin E2 as a mediator of fever: synthesis and catabolism. Front Biosci (2004) 1.57

EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma. Acta Oncol (1998) 1.39

Apc deficiency is associated with increased Egfr activity in the intestinal enterocytes and adenomas of C57BL/6J-Min/+ mice. J Biol Chem (2004) 1.35

Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas. Tumour Biol (2000) 1.31

Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene (1999) 1.31

Cloning and characterization of a growth factor-inducible cyclooxygenase gene from rat intestinal epithelial cells. Am J Physiol (1994) 1.23

Prostaglandin E2 synergistically enhances receptor tyrosine kinase-dependent signaling system in colon cancer cells. J Biol Chem (2004) 1.14

Cytokeratin 20, AN43, PGDH, and COX-2 expression in transitional and squamous cell carcinoma of the bladder. Urol Oncol (2003) 1.09

Enhancement of experimental colon cancer by genistein. Cancer Res (1997) 1.07

Intestinal immune responses in wild-type and Apcmin/+ mouse, a model for colon cancer. Cancer Res (2003) 1.05

Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapy. Cancer Res (2003) 1.04

Prostanoids, ornithine decarboxylase, and polyamines in primary chemoprevention of familial adenomatous polyposis. Gastroenterology (2004) 1.01

Enzymatic synthesis of (15s)-[15-3h]prostaglandins and their use in the development of a simple and sensitive assay for 15-hydroxyprostaglandin dehydrogenase. Biochemistry (1976) 0.98

Synergistic induction of the nicotinamide adenine dinucleotide-linked 15-hydroxyprostaglandin dehydrogenase by an androgen and interleukin-6 or forskolin in human prostate cancer cells. Endocrinology (2004) 0.97

Induction of NAD(+)-linked 15-hydroxyprostaglandin dehydrogenase expression by androgens in human prostate cancer cells. Biochem Biophys Res Commun (2000) 0.94

Tumor growth inhibition by indomethacin in a mouse model of human medullary thyroid cancer: implication of cyclooxygenases and 15-hydroxyprostaglandin dehydrogenase. Endocrinology (2004) 0.93

Chromosomal localization of the type-I 15-PGDH gene to 4q34-q35. Hum Genet (1997) 0.93

Indomethacin, a cox inhibitor, enhances 15-PGDH and decreases human tumoral C cells proliferation. Prostaglandins Other Lipid Mediat (2001) 0.93

Thiazolidinediones as a novel class of NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase inhibitors. Arch Biochem Biophys (2002) 0.92

Cyclooxygenase-2 and colorectal cancer. Prog Exp Tumor Res (2003) 0.91

Inhibition of NAD+-dependent 15-hydroxyprostaglandin dehydrogenase (15-PGDH) by cyclooxygenase inhibitors and chemopreventive agents. Prostaglandins Leukot Essent Fatty Acids (2002) 0.91

Genomic structure and transcriptional regulation of the human NAD+-dependent 15-hydroxyprostaglandin dehydrogenase gene. J Mol Endocrinol (2003) 0.89

Indomethacin increases 15-PGDH mRNA expression in HL60 cells differentiated by PMA. Prostaglandins Leukot Essent Fatty Acids (2001) 0.86

Frontiers in cancer prevention research. Cancer Res (2003) 0.82

COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol (2005) 3.15

Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem (2003) 2.65

Computational redesign of human butyrylcholinesterase for anticocaine medication. Proc Natl Acad Sci U S A (2005) 2.63

Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta. Cancer Cell (2004) 2.60

Quantification of F2-isoprostanes as a biomarker of oxidative stress. Nat Protoc (2007) 2.56

15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers. Proc Natl Acad Sci U S A (2004) 2.42

Most efficient cocaine hydrolase designed by virtual screening of transition states. J Am Chem Soc (2008) 2.33

CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J Exp Med (2006) 2.30

NSAIDs and cancer prevention: targets downstream of COX-2. Annu Rev Med (2007) 2.19

Cyclooxygenase-2: a therapeutic target. Annu Rev Med (2002) 2.16

Interaction of electrophilic lipid oxidation products with mitochondria in endothelial cells and formation of reactive oxygen species. Am J Physiol Heart Circ Physiol (2005) 2.12

Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes. Blood (2012) 2.08

Levels of prostaglandin E metabolite and leukotriene E(4) are increased in the urine of smokers: evidence that celecoxib shunts arachidonic acid into the 5-lipoxygenase pathway. Cancer Prev Res (Phila) (2009) 2.06

Differential stem- and progenitor-cell trafficking by prostaglandin E2. Nature (2013) 1.99

Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol (2005) 1.98

Role of beta-arrestin 1 in the metastatic progression of colorectal cancer. Proc Natl Acad Sci U S A (2006) 1.97

Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-delta accelerates intestinal adenoma growth. Nat Med (2004) 1.89

The effect of HIV and HPV coinfection on cervical COX-2 expression and systemic prostaglandin E2 levels. Cancer Prev Res (Phila) (2011) 1.85

Crosstalk between peroxisome proliferator-activated receptor delta and VEGF stimulates cancer progression. Proc Natl Acad Sci U S A (2006) 1.84

The role of prostaglandins and other eicosanoids in the gastrointestinal tract. Gastroenterology (2005) 1.83

15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res (2006) 1.82

COX-2: a target for colon cancer prevention. Annu Rev Pharmacol Toxicol (2002) 1.80

Molecular dynamics simulation of cocaine binding with human butyrylcholinesterase and its mutants. J Phys Chem B (2005) 1.73

NAD+-dependent 15-hydroxyprostaglandin dehydrogenase regulates levels of bioactive lipids in non-small cell lung cancer. Cancer Prev Res (Phila) (2008) 1.71

Prostaglandin E2 enhances intestinal adenoma growth via activation of the Ras-mitogen-activated protein kinase cascade. Cancer Res (2005) 1.68

15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors. Proc Natl Acad Sci U S A (2009) 1.65

Connecting COX-2 and Wnt in cancer. Cancer Cell (2006) 1.59

Salt-sensitive hypertension is associated with dysfunctional Cyp4a10 gene and kidney epithelial sodium channel. J Clin Invest (2006) 1.59

Circadian clock proteins regulate neuronal redox homeostasis and neurodegeneration. J Clin Invest (2013) 1.57

NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer. Carcinogenesis (2004) 1.57

Computational design of a human butyrylcholinesterase mutant for accelerating cocaine hydrolysis based on the transition-state simulation. Angew Chem Int Ed Engl (2006) 1.55

Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. Cancer Res (2003) 1.53

Aberrant cannabinoid signaling impairs oviductal transport of embryos. Nat Med (2004) 1.52

Altered inflammatory, oxidative, and metabolic responses to exercise in pediatric obesity and type 1 diabetes. Pediatr Diabetes (2011) 1.51

Dietary intake of PUFAs and colorectal polyp risk. Am J Clin Nutr (2012) 1.51

Targeted lipidomics using electron capture atmospheric pressure chemical ionization mass spectrometry. Rapid Commun Mass Spectrom (2003) 1.50

Design, preparation, and characterization of high-activity mutants of human butyrylcholinesterase specific for detoxification of cocaine. Mol Pharmacol (2010) 1.48

Prostaglandin E2 promotes intestinal tumor growth via DNA methylation. Nat Med (2012) 1.47

Preventive effects of NSAIDs, NO-NSAIDs, and NSAIDs plus difluoromethylornithine in a chemically induced urinary bladder cancer model. Cancer Prev Res (Phila) (2013) 1.45

F2-isoprostanes as markers of oxidative stress in vivo: an overview. Biomarkers (2005) 1.44

Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward. Clin Cancer Res (2010) 1.44

15-Lipoxygenase metabolism of 2-arachidonylglycerol. Generation of a peroxisome proliferator-activated receptor alpha agonist. J Biol Chem (2002) 1.43

Cyclooxygenase as a target in lung cancer. Clin Cancer Res (2004) 1.43

The role of anti-inflammatory drugs in colorectal cancer. Annu Rev Med (2012) 1.40

Loss of cannabinoid receptor 1 accelerates intestinal tumor growth. Cancer Res (2008) 1.39

Requirement of phospholipase D1 activity in H-RasV12-induced transformation. Proc Natl Acad Sci U S A (2005) 1.38

Mechanisms for the prevention of gastrointestinal cancer: the role of prostaglandin E2. Oncology (2005) 1.37

Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer. Cancer Res (2005) 1.36

Oxidative stress and matrix metalloproteinase-9 in acute ischemic stroke: the Biomarker Evaluation for Antioxidant Therapies in Stroke (BEAT-Stroke) study. Stroke (2007) 1.35

Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular system. Proc Natl Acad Sci U S A (2012) 1.35

Pro-inflammatory prostaglandins and progression of colorectal cancer. Cancer Lett (2008) 1.32

Cyclooxygenase-1-derived PGE2 promotes cell motility via the G-protein-coupled EP4 receptor during vertebrate gastrulation. Genes Dev (2006) 1.28

Inflammation in the genesis and perpetuation of cancer: summary and recommendations from a national cancer institute-sponsored meeting. Cancer Res (2005) 1.27

Mechanisms of disease: Inflammatory mediators and cancer prevention. Nat Clin Pract Oncol (2005) 1.27

Electrophilic cyclopentenone neuroprostanes are anti-inflammatory mediators formed from the peroxidation of the omega-3 polyunsaturated fatty acid docosahexaenoic acid. J Biol Chem (2008) 1.26

Repression of prostaglandin dehydrogenase by epidermal growth factor and snail increases prostaglandin E2 and promotes cancer progression. Cancer Res (2006) 1.26

Free-energy perturbation simulation on transition states and redesign of butyrylcholinesterase. Biophys J (2009) 1.25

Formation of F-ring isoprostane-like compounds (F3-isoprostanes) in vivo from eicosapentaenoic acid. J Biol Chem (2006) 1.25

Levels of NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase are reduced in inflammatory bowel disease: evidence for involvement of TNF-alpha. Am J Physiol Gastrointest Liver Physiol (2005) 1.24

15-hydroxyprostaglandin dehydrogenase is down-regulated in gastric cancer. Clin Cancer Res (2009) 1.23

Energy expenditure, inflammation, and oxidative stress in steady-state adolescents with sickle cell anemia. Pediatr Res (2007) 1.20

A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer. Clin Cancer Res (2006) 1.18

Increased levels of urinary PGE-M, a biomarker of inflammation, occur in association with obesity, aging, and lung metastases in patients with breast cancer. Cancer Prev Res (Phila) (2013) 1.17

Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer. Cancer Res (2007) 1.17

Prostaglandin E2 regulates the nuclear receptor NR4A2 in colorectal cancer. J Biol Chem (2005) 1.15

The effect of vitamins C and E on biomarkers of oxidative stress depends on baseline level. Free Radic Biol Med (2008) 1.15

Formation of highly reactive cyclopentenone isoprostane compounds (A3/J3-isoprostanes) in vivo from eicosapentaenoic acid. J Biol Chem (2008) 1.15

Regulation of prostaglandin transporters in colorectal neoplasia. Cancer Prev Res (Phila) (2008) 1.15

Isoprostanes. J Lipid Res (2008) 1.14

Fishing for prostanoids: deciphering the developmental functions of cyclooxygenase-derived prostaglandins. Dev Biol (2005) 1.14

Inhibition of epidermal growth factor receptor signaling elevates 15-hydroxyprostaglandin dehydrogenase in non-small-cell lung cancer. Cancer Res (2007) 1.14

Inherited human cPLA(2alpha) deficiency is associated with impaired eicosanoid biosynthesis, small intestinal ulceration, and platelet dysfunction. J Clin Invest (2008) 1.12

Formation of prostaglandins E2 and D2 via the isoprostane pathway: a mechanism for the generation of bioactive prostaglandins independent of cyclooxygenase. J Biol Chem (2003) 1.11

Urinary prostaglandin F2alpha is generated from the isoprostane pathway and not the cyclooxygenase in humans. J Biol Chem (2006) 1.09

Peroxisome proliferator-activated receptors modulate K-Ras-mediated transformation of intestinal epithelial cells. Cancer Res (2002) 1.07

COX-2 in cancer--a player that's defining the rules. J Natl Cancer Inst (2002) 1.06

Novel human mPGES-1 inhibitors identified through structure-based virtual screening. Bioorg Med Chem (2011) 1.05

Reciprocal regulation of cyclooxygenase-2 and 15-hydroxyprostaglandin dehydrogenase expression in A549 human lung adenocarcinoma cells. Carcinogenesis (2006) 1.05

Mitochondria-targeted cytochrome P450 2E1 induces oxidative damage and augments alcohol-mediated oxidative stress. J Biol Chem (2010) 1.05

Cyclopentenone isoprostanes inhibit the inflammatory response in macrophages. J Biol Chem (2005) 1.05

Prostaglandin E2 deficiency uncovers a dominant role for thromboxane A2 in house dust mite-induced allergic pulmonary inflammation. Proc Natl Acad Sci U S A (2012) 1.04

Cyclooxygenase 2-derived prostaglandin E2 regulates the angiogenic switch. Proc Natl Acad Sci U S A (2004) 1.04

Peroxisome proliferator-activated receptor beta/delta expression and activation in lung cancer. Am J Respir Cell Mol Biol (2008) 1.04

Repression of 15-hydroxyprostaglandin dehydrogenase involves histone deacetylase 2 and snail in colorectal cancer. Cancer Res (2008) 1.04

Cyclopentenone isoprostanes are novel bioactive products of lipid oxidation which enhance neurodegeneration. J Neurochem (2006) 1.03